ArticleCureus2025
Granulomatous Mastitis-Related Large Skin Defect in a Patient With Ulcerative Colitis on Mesalazine Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 30-year-old woman with ulcerative colitis on mesalazine therapy developed a breast mass seven months after her first child delivery. Breast massage to the affected breast and drainage of the abscess cavity only resulted in skin necrosis just above the breast mass followed by skin defect formation larger than 10cm in size. A pathological study of the exposed breast tissue led to the diagnosis of granulomatous mastitis (GM). Due to the shrunken but still large skin defect after successful steroid therapy, the patient underwent latissimus dorsi musculocutaneous (LDMC) flap grafting in order to get both better cosmetic outcomes and a shorter treatment period. The patient was discharged without any complications on the eighth day after the operation and has been well with excellent cosmetic outcomes while taking care of her child for 31 months. In conclusion, mesalazine therapy might correlate with this type of large skin defect formation in GM. Breast surgeons should note that LDMC flap grafting can be a feasible therapeutic option to cover large skin defects even in GM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.